CYR61 was found to be downregulated in the majority of the 22 cancer types, such as breast cancer (BRCA), adrenocortical cancer (ACC), bladder cancer (BLCA), and cervical cancer (CESC), whereas upregulated in glioblastoma (GBM), pancreatic carcinoma (PAAD), large B-cell lymphoma (DLBC), and thymoma (THYM) (Figure 1A). This evidence concerns the gene CCN1 and breast carcinoma.